Current Value
$0.321 Year Return
Current Value
$0.321 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
AGS | -19.10% | $500.47M | +38.15% | 0.00% |
CBOE | -18.63% | $23.50B | +25.53% | 1.05% |
CME | -18.29% | $94.61B | +23.82% | 3.89% |
RPRX | -15.64% | $13.55B | +8.61% | 2.68% |
NOC | -14.30% | $74.14B | +12.07% | 1.60% |
MNOV | -13.72% | $69.16M | -7.24% | 0.00% |
AEP | -11.69% | $57.54B | +27.77% | 3.31% |
CI | -11.62% | $89.99B | -8.07% | 1.68% |
PG | -11.30% | $397.45B | +8.55% | 2.32% |
CHD | -11.29% | $26.66B | +5.00% | 1.03% |
MKTX | -10.72% | $7.95B | -1.91% | 1.34% |
KMB | -10.47% | $47.39B | +13.36% | 3.37% |
CL | -10.11% | $75.88B | +6.19% | 2.07% |
MO | -10.08% | $96.57B | +35.61% | 6.83% |
PEP | -9.69% | $204.52B | -12.12% | 3.52% |
CNC | -9.38% | $30.13B | -16.85% | 0.00% |
CF | -9.11% | $13.29B | -4.06% | 2.51% |
CLX | -9.09% | $18.19B | +0.54% | 3.24% |
ES | -8.77% | $22.99B | +7.19% | 4.61% |
TSN | -8.61% | $21.91B | +8.55% | 3.09% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
DBA | 0.10% | $829.48M | 0.93% |
CARY | -0.12% | $347.36M | 0.8% |
AGZ | -0.18% | $644.13M | 0.2% |
BSMR | 0.19% | $235.44M | 0.18% |
CMBS | 0.23% | $432.98M | 0.25% |
SMMU | -0.24% | $684.32M | 0.35% |
BSMW | -0.27% | $101.29M | 0.18% |
MLN | -0.29% | $534.56M | 0.24% |
SHV | -0.31% | $20.16B | 0.15% |
IBTG | 0.37% | $1.82B | 0.07% |
TLH | -0.42% | $10.21B | 0.15% |
GOVI | -0.47% | $1.07B | 0.15% |
TPMN | 0.49% | $33.32M | 0.65% |
TAXF | -0.51% | $517.32M | 0.29% |
BSSX | 0.67% | $76.01M | 0.18% |
FTGC | -0.72% | $2.52B | 1.02% |
BILS | -0.76% | $3.67B | 0.1356% |
IBTP | -0.79% | $111.57M | 0.07% |
JPLD | 0.85% | $1.15B | 0.24% |
GBIL | -0.87% | $6.30B | 0.12% |
Yahoo
CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that Phase 1 dose escalation and backfill cohort clinical data for emiltatug ledadotin (Emi-Le; XMT-1660) will be presented in an oral session at the ESMO Breast Cancer 2025 Annual Congress, which is being
Yahoo
Mersana Therapeutics, Inc. ( NASDAQ:MRSN ) investors will be delighted, with the company turning in some strong numbers...
Yahoo
Mersana Therapeutics, Inc. ( NASDAQ:MRSN ) shareholders will have a reason to smile today, with the analysts making...
Yahoo
Mersana Therapeutics ( NASDAQ:MRSN ) Full Year 2024 Results Key Financial Results Revenue: US$40.5m (up 9.9% from FY...
Yahoo
Mersana Therapeutics Inc (MRSN) reports promising clinical progress and improved financial metrics, positioning itself strongly for future growth.
Yahoo
Q4 2024 Mersana Therapeutics Inc Earnings Call
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
CPRJ | 57.90% | $48.38M | 0.69% |
RSPA | 48.86% | $292.67M | 0% |
XBI | 42.80% | $4.76B | 0.35% |
IWC | 42.39% | $797.08M | 0.6% |
IWO | 42.21% | $10.72B | 0.24% |
QQA | 42.18% | $187.77M | 0% |
VTWO | 41.61% | $10.92B | 0.07% |
IWM | 41.59% | $62.65B | 0.19% |
GNOM | 41.57% | $47.13M | 0.5% |
KJAN | 41.40% | $317.59M | 0.79% |
KAPR | 41.12% | $144.85M | 0.79% |
GSSC | 41.04% | $514.19M | 0.2% |
SCHA | 40.59% | $15.94B | 0.04% |
RYLD | 40.57% | $1.38B | 0.6% |
ISCG | 40.36% | $655.02M | 0.06% |
ESML | 40.08% | $1.76B | 0.17% |
VBK | 39.91% | $17.32B | 0.07% |
VXF | 39.56% | $19.92B | 0.05% |
SMMD | 39.54% | $1.29B | 0.15% |
IWN | 39.24% | $10.95B | 0.24% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
RGNX | 41.92% | $353.11M | -65.19% | 0.00% |
DYN | 41.10% | $1.12B | -65.54% | 0.00% |
IGMS | 40.59% | $73.52M | -86.38% | 0.00% |
DNLI | 40.50% | $2.00B | -29.07% | 0.00% |
CRNX | 40.32% | $2.92B | -34.08% | 0.00% |
PLAB | 38.52% | $1.30B | -27.97% | 0.00% |
NEO | 38.41% | $1.21B | -36.65% | 0.00% |
VYX | 37.31% | $1.38B | -18.97% | 0.00% |
ALNT | 36.56% | $374.22M | -33.95% | 0.59% |
CTS | 36.26% | $1.26B | -6.74% | 0.43% |
BNT | 36.23% | $10.90B | +33.38% | 0.00% |
AIFU | 36.22% | $11.90M | -95.45% | 0.00% |
JEF | 36.15% | $11.37B | +24.86% | 2.90% |
BN | 35.84% | $81.49B | +33.48% | 0.65% |
ACLX | 35.71% | $3.69B | +6.38% | 0.00% |
RMBS | 34.89% | $5.66B | -12.65% | 0.00% |
PSMT | 34.81% | $2.73B | +10.91% | 1.40% |
SXT | 34.70% | $3.21B | +10.24% | 2.20% |
ACA | 34.64% | $3.97B | -2.61% | 0.27% |
CADE | 34.45% | $5.57B | +10.32% | 3.66% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -28.99% | $416.76M | 1.43% |
VIXY | -25.87% | $195.31M | 0.85% |
TAIL | -21.89% | $87.65M | 0.59% |
CTA | -14.60% | $978.30M | 0.76% |
CORN | -10.79% | $52.17M | 0.2% |
UNG | -10.63% | $397.59M | 1.06% |
WEAT | -10.18% | $115.75M | 0.28% |
SOYB | -9.76% | $26.08M | 0.22% |
FXY | -9.14% | $549.84M | 0.4% |
USDU | -9.11% | $206.96M | 0.5% |
BIL | -7.67% | $41.88B | 0.1356% |
TBLL | -7.10% | $2.13B | 0.08% |
IBMN | -6.93% | $472.63M | 0.18% |
XHLF | -6.48% | $1.06B | 0.03% |
DBE | -6.47% | $55.52M | 0.77% |
CCOR | -5.96% | $64.12M | 1.18% |
IYK | -5.75% | $1.53B | 0.4% |
TBIL | -5.21% | $5.39B | 0.15% |
SGOV | -5.18% | $39.98B | 0.09% |
ULST | -5.08% | $585.14M | 0.2% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
MKC | 0.01% | $21.80B | +6.61% | 2.08% |
TR | 0.06% | $2.24B | +3.83% | 1.15% |
NEUE | -0.09% | $57.12M | +4.27% | 0.00% |
XIFR | 0.09% | $869.87M | -67.92% | 29.95% |
AZO | -0.11% | $63.72B | +21.06% | 0.00% |
AMN | 0.13% | $891.99M | -59.96% | 0.00% |
IPI | -0.13% | $395.60M | +41.69% | 0.00% |
DXCM | 0.13% | $26.63B | -50.81% | 0.00% |
TTEK | 0.14% | $8.26B | -19.20% | 2.32% |
CCI | 0.16% | $45.20B | +1.61% | 5.85% |
ABBV | 0.17% | $362.98B | +15.71% | 3.07% |
CYD | 0.19% | $670.08M | +96.41% | 2.39% |
SO | -0.20% | $100.14B | +28.63% | 3.09% |
FLO | -0.21% | $4.00B | -18.06% | 5.03% |
VZ | 0.23% | $188.34B | +4.44% | 5.84% |
KR | -0.26% | $48.68B | +16.46% | 1.77% |
SYPR | 0.27% | $37.52M | -3.55% | 0.00% |
HUM | 0.29% | $32.08B | -13.72% | 1.31% |
TXO | -0.29% | $766.54M | +1.64% | 13.46% |
BJ | -0.32% | $15.14B | +54.61% | 0.00% |